Related Experiment Video
Updated: Oct 2, 2025
09:54
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
3.7K
Regulatory T-cell Changes in Patients with Steroid-Resistant Nephrotic Syndrome after Rituximab Therapy
Seçil Conkar Tunçay1, Gülden Hakverdi2, Özgür Şenol3
1Department of Pediatric Nephrology, Ege University Faculty of Medicine, Izmir, Turkey.
Summary
Rituximab (RTX) treatment in children with steroid-resistant nephrotic syndrome (SRNS) significantly reduced B-cells and increased regulatory T-cells (Tregs), leading to a 70% remission rate.
Area of Science:
- Immunology
- Pediatric Nephrology
- Cell Biology
Background:
- Steroid-resistant nephrotic syndrome (SRNS) is a serious condition in children.
- The underlying mechanisms of SRNS involve complex immune dysregulation.
- Rituximab (RTX) is an immunosuppressive therapy used for various autoimmune conditions.
Purpose of the Study:
- To investigate the impact of rituximab (RTX) on immunoglobulin levels and specific immune cell populations in children with SRNS.
- To evaluate the efficacy of RTX in achieving remission in pediatric SRNS patients.
Main Methods:
- A cross-sectional cohort study involving 23 children with SRNS and 20 healthy controls.
- Serum immunoglobulin (IgA, IgG, IgM) levels were measured.
- Flow cytometry was used to quantify B cells (CD19+) and T regulatory cells (Tregs, CD4+CD25+FoxP3+) before and one month after RTX treatment.
- RTX was administered at 375 mg/m²/week for four doses.
Main Results:
- Before RTX treatment, SRNS patients had significantly lower Treg percentages and IgG levels compared to controls.
- RTX treatment led to a significant decrease in B-cell numbers one month post-treatment.
- A significant increase in Treg cell percentages was observed one month after RTX treatment.
- Seventy percent (11/23) of SRNS patients achieved remission with RTX therapy.
Conclusions:
- Rituximab therapy effectively depletes B-cells in pediatric SRNS patients.
- RTX treatment promotes an increase in regulatory T-cell populations in SRNS patients.
- RTX demonstrates significant efficacy in inducing remission for SRNS in children, suggesting a role in immune modulation.
Related Concept Videos
01:24T Cell Types and Functions
1.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.5K
01:24Nephrotic Syndrome III : Nursing Management
62
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
62
01:26Nephrotic Syndrome II : Assessment and Medical Management
33
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
33
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
01:24Nephrotic Syndrome I : Introduction
43
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
43